楼主: bigfoot0517
2830 3

[外行报告] 瑞士信贷--美国医药行业研究报告2008年7月 [推广有奖]

  • 1关注
  • 21粉丝

已卖:14110份资源

学术权威

21%

还不是VIP/贵宾

-

威望
6
论坛币
12493638 个
通用积分
3.1784
学术水平
391 点
热心指数
369 点
信用等级
405 点
经验
28609 点
帖子
2147
精华
2
在线时间
242 小时
注册时间
2006-11-15
最后登录
2019-1-31

楼主
bigfoot0517 发表于 2008-7-16 13:53:00 |AI写论文

+2 论坛币
k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群
赵安豆老师微信:zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

感谢您参与论坛问题回答

经管之家送您两个论坛币!

+2 论坛币

US Major Pharmaceuticals
COMMENT
Price and Currency Still Reign in Pharma
Quarter

Aggregate year-over-year EPS growth for 2Q08 should be strong, at 8%
(compared to 5% in 1Q08). However this growth contains wide disparities
among individual stocks. Stocks we expect to report double-digit growth
include ABT (14.8%), BMY (14.5%) and PFE (12.9%). We see more modest
growth for LLY (6.1%), JNJ (3.9%) and SGP (2.6%, in part due to
ENHANCE and Organon interest expense), and negative growth for WYE (-
2.7%, Protonix generics) and MRK (-1.6%, Fosamax generics).

Once again, foreign exchange will provide a tailwind to group earnings, as
the dollar declines sequentially against the Euro for the tenth consecutive
quarter (down 4.2% over 1Q08 and 13.7% over 2Q07). All 8 companies
source over 40% of sales internationally, and 4 are over 50%.

Price increases were strong across the group in 2Q08, with a volumeweighted
year over year average of 6.3%. PFE, ABT, LLY and JNJ had the
highest average increases (all over 7%), and even WYE, which traditionally
lags the group, raised its average increase from 1.2% to 4.2%.

We are significantly above 2Q 2008 consensus for SGP ($0.02, or 4.2%),
and significantly below consensus on PFE ($0.05, or 9.9%) and MRK ($0.03,
or 4.2%). For the full year 2008, we are most different on SGP (+$0.10, or
6.2%) and PFE (-$0.06, or 2.6%).

In preparation for 2Q 2008 results, we have fine-tuned our models, leading
to the following EPS changes explained in each company section.

ABT 2008 EPS: old $3.24, new $3.25, and 2009 EPS: old $3.60, new $3.62.

BMY 2008 EPS: old $1.67, new $1.64, and 2009 EPS: old $1.96, new $1.95.

JNJ 2008 EPS: old $4.40, new $4.43, and 2009 EPS: remains $4.45.

LLY 2008 EPS: old $3.89, new $3.95, and 2009 EPS: old $4.22, new $4.30.

MRK 2008 EPS old $3.28, new $3.29, and 2009 EPS old $3.68, new $3.70.

PFE 2008 EPS: old $2.27, new $2.29, and 2009 EPS: old $2.41, new $2.44.

SGP 2008 EPS: old $1.62, new $1.63, and 2009 EPS: remains $1.94.

WYE 2008 EPS: remains $3.47, and 2009 EPS: remains $3.77.

227921.pdf (953.23 KB, 需要: 10 个论坛币)


二维码

扫码加我 拉你入群

请注明:姓名-公司-职位

以便审核进群资格,未注明则拒绝

关键词:行业研究报告 医药行业 研究报告 行业研究 瑞士信贷 美国 研究报告 信贷 瑞士 医药行业

沙发
zzhenheng(真实交易用户) 在职认证  发表于 2008-10-26 09:08:00

thanks a lot

自主者天成

藤椅
duxijie520(未真实交易用户) 发表于 2008-10-26 10:10:00
非常感谢

板凳
naga69c(未真实交易用户) 发表于 2008-10-27 09:01:00
看上去很好啊。

您需要登录后才可以回帖 登录 | 我要注册

本版微信群
jg-xs1
拉您进交流群
GMT+8, 2025-12-9 13:54